Price cut secures UK reimbursement for Boehringer's Vargatef
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has convinced UK health technology appraisal body NICE to make a U-turn on its previous decision not to reimburse its lung cancer therapy Vargatef (nintedanib).